Kuros Biosciences AG
0RHR.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$946.55M
Close$
Share Statistics
| Market cap | $946.55 Million |
|---|---|
| Enterprise Value | $949.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.06 |
| Beta | 0.76 |
| Outstanding Shares | 39,458,790 |
Return
| Return on Equity | 1.42% |
|---|---|
| Return on Assets | 0.85% |
| Return on Invested Capital | 9.72% |
Valuation & Multiples
| P/E Ratio | 101.38 |
|---|---|
| PEG | -37.25 |
| Price to Sales | 3.04 |
| Price to Book Ratio | 18.25 |
| Enterprise Value to Revenue | 3.86 |
| Enterprise Value to EBIT | 115.92 |
| Enterprise Value to Net Income | 927 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$73.56 M
Average shareholder expectationNext Earnings Call
Expected Date
March 17, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$92.83 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kuros Biosciences AG
178 employees
CEO: Christopher T. Fair Kuros Biosciences AG operates as a biopharmaceutical firm, concentrating on the commercialization and advancement of products designed for tissue repair and bone regeneration. Its operations span the United States, the European Union, an...